Business context and reporting period
This is Celsion Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2019 (filed May 15, 2019). The filing identifies the issuer as Celsion Corporation, ticker CLSN; it does not identify Imunon as the issuer. Celsion is a clinical-stage oncology company developing ThermoDox, a Phase III candidate for primary liver cancer, and GEN-1, an ovarian cancer immunotherapy.
Financial results and liquidity
- Revenue: $125,000, unchanged from Q1 2018; entirely technology development and licensing revenue recognized from a previously received Hisun payment. The company reported no product revenue.
- Operating costs and loss: R&D expense was $2.77 million (up 0.9%); G&A was $2.22 million (up 33.2%). Total operating expenses rose 13.2% to $4.99 million, and operating loss widened 13.5% to $4.86 million.
- Net loss: $2.37 million, versus $4.48 million in Q1 2018; loss per share was $0.12 versus $0.25. The improvement primarily reflects a noncash $3.13 million gain from revaluing the EGEN earn-out liability, partly offset by a $400,000 warrant expense and $351,000 interest expense.
- Cash flow: Operating cash use was $5.54 million, compared with $4.66 million in Q1 2018. Investing cash use was $6.00 million, largely reflecting purchases of short-term investments; financing provided $1.75 million from equity sales. Cash and cash equivalents fell to $3.58 million from $13.35 million at year-end.
- Liquidity: Cash, investments and accrued interest totaled approximately $23.8 million at quarter-end. Current assets were $24.86 million and current liabilities $5.89 million, yielding working capital of approximately $19.0 million, down from $22.0 million at December 31, 2018.
- Debt and obligations: The Horizon term loan had $10.0 million principal outstanding and a $9.51 million net carrying value, with interest at one-month LIBOR plus 7.625%. Interest-only payments apply for the first 24 months, followed by 24 months of principal and interest. The loan is secured by substantially all assets other than intellectual property. Lease liabilities totaled $1.78 million.
- Equity and assets: Total assets were $45.40 million and stockholders’ equity $21.40 million. Shares outstanding were 19.66 million at March 31 and 20.48 million as of May 14, 2019.
Material changes versus the prior comparable period
- Net loss narrowed by approximately $2.11 million, mainly due to the earn-out fair-value gain; operating loss nevertheless increased by $579,000 as operating expenses grew.
- G&A increased by $553,000, attributed mainly to higher personnel costs and stock-based compensation. R&D increased modestly: lower OPTIMA study costs were largely offset by higher manufacturing, regulatory and other clinical costs.
- Q1 2019 included $351,000 of interest expense on the Horizon loan; no interest expense was reported in Q1 2018.
- Cash and cash equivalents decreased substantially, while available-for-sale corporate debt securities increased to $20.17 million from $14.26 million at year-end. Net working capital also declined.
Outlook, commentary and risks
- Management expected available resources, together with anticipated New Jersey net operating loss sales, to fund operations into Q4 2020. The company expected continuing operating losses and stated that additional funding would be required to advance its candidates and sustain operations.
- Approximately $28.6 million remained available at March 31 under the Aspire Capital purchase agreement and JonesTrading sales agreement. These are potential equity financing sources, not guaranteed proceeds; use may dilute existing shareholders.
- The 556-patient OPTIMA Phase III trial had completed enrollment in August 2018. Interim efficacy analyses were expected in the second half of 2019 and mid-2020; a final analysis, if needed, was expected in the first half of 2021. The DMC had recommended continuing the study after its last scheduled review. The prior HEAT Phase III study failed its primary endpoint, and the positive ThermoDox rationale relies in part on retrospective subgroup analyses.
- On March 28, 2019, Celsion amended the EGEN earn-out terms: upon milestone achievement, it may pay $7.0 million in cash within 10 business days, or $12.4 million in cash, stock, or a combination within one year. The amendment was accompanied by 200,000 warrants exercisable at $0.01. The quarter-end $5.78 million earn-out liability is a probability-weighted fair-value estimate, not the maximum potential payment.
- Principal risks include clinical and regulatory failure or delay, reliance on external trial and manufacturing partners, substantial future capital needs and possible dilution, product safety and commercialization uncertainty, and the possibility that ThermoDox will not succeed despite OPTIMA’s progress. The company reported no legal proceedings and no off-balance-sheet arrangements.
- ASC 842 adoption added operating lease right-of-use assets and liabilities to the balance sheet, with no material effect on opening retained earnings or reported cash flows. Management reported disclosure controls effective at the reasonable-assurance level.
Important facts for investors to verify
- Confirm the issuer and security being reviewed: this filing is for Celsion Corporation (CLSN), despite the request metadata naming Imunon.
- Track OPTIMA interim and final readout timing, data quality, and whether results support the retrospective HEAT subgroup hypothesis.
- Reconcile the stated runway through Q4 2020 with quarterly operating cash use, anticipated New Jersey NOL proceeds, and actual equity financing availability.
- Assess dilution from Aspire and JonesTrading sales, subsequent post-quarter share issuances, and outstanding options and warrants.
- Review the Horizon loan’s variable-rate cost, collateral and repayment schedule, and the contingent EGEN milestone payment alternatives.